Global Tylosin Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
世界におけるタイロシン市場の成長は、畜産業におけるタイロシンの需要の高まりによって推進されています。タイロシンは、Brachyspira Hyodysenteriae (ブラキスピラ・ヒオディセンテリア:豚赤痢原因菌) に関連する豚赤痢の治療と管理、および豚の豚増殖性腸疾患の管理に使用されます。さらに、タイロシンは、タイロシン治療に繰り返し反応するイヌの慢性、再発性下痢であるタイロシン反応性下痢 (TRD) に非常に効果的です。
The global tylosin market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Tylosin is an antibiotic of the macrolide class developed for veterinary use. Tylosin is licensed for use as a broad spectrum antibiotic for injectable or oral use in treatment of infection such as respiratory tract and skin infections in livestock. It may also be used as a growth promoter in food animals.
The global tylosin market growth is driven by the rising demand for tylosin in livestock industry. Tylosin is used for treatment and control of swine dysentery associated with Brachyspira Hyodysenteriae and for the control of porcine proliferate enteropathies in pigs. Moreover, Tylosin is highly effective in tylosin-responsive diarrhea in dogs, which is a canine chronic, recurrent diarrhea that responds repeatedly to tylosin treatment.
The global tylosin market is expected to witness significant growth over the forecast period, owing to rising demand for tylosin in livestock industry. For instance, according to a study by Ministry for Primary Industries, New Zealand 2016, tylosin accounted for over 83% of macrolide and lincosamide sales during 2011 and 2014 and the trend is expected to continue over the forecast period.
Antimicrobial medications are generally used in the livestock industry for treatment of various infections in the livestock, prevention of disease, and to improve growth rate of the animals efficiency. Moreover, antimicrobial medications have been found to be effective in animals for improving growth rate and increasing weight more efficiently, which in turn results in increasing profits for the meat producers.
Rising income levels and disposable income in emerging economies has increase in demand for healthy protein sources for consumption as daily protein need of the body is not met through conventional food sources. According to NCBI, 2015, in Asia, the daily animal protein intake increased from 7 grams per capita per day to 25 grams per capita per day between 1960, and 2013. Countries such as Brazil, Russia, India, China, and South Africa (BRICS) have started implementing intensive livestock production systems to meet this demand (which necessitates use of antimicrobials). These factors are expected to support growth of the global Tylosin market over the forecast period.
The most common side effects of tylosin use include pain and inflammation at the injection site and mild gastrointestinal upset, such as decreased appetite and diarrhea. This short-acting medication should stop working within 24 hours, although effects can be longer in pets with liver or kidney disease.
The effects of COVID-19 on the livestock medications are still largely unquantified and yet to be fully felt. Movement restrictions and illness are resulting in tylosin shortages and reduced supply of raw materials or other API to its production. Disruption of supply routes has further delayed its supply. In China the world's biggest tylosin exporter restrictions have reduced its production in the factories by half, which could affect global trade flows. Thus, the pandemic has decreased the sale which hamper the global tylosin market in the forecast period.
Tylosin tartrate is a particular type of antibiotic that is commonly used in a variety of animals, including dogs, cats, cattle, horses and more. This antibiotic serves a wide range of different purposes, but like other antibiotics it is designed specifically to target and kill certain types of bacteria. Without treating these bacteria, your pet may run the risk of developing an infection. In terms of its effects on animals. In dogs, tylosin tartrate is most commonly used to treat both gastric infections in general and colitis in particular. Colitis, which is characterized by irritable bowels and a lack of proper consistency in bowel movements, as well as excessive flatulence and general stomach upset, is caused by an influx of harmful bacteria in the gut and digestive tract. Regular treatments of tylosin tartrate have been shown to help eliminate this bacteria, particularly in smaller animals.
The demand for livestock animals for consumption is on the rise worldwide and is expected to maintain the positive growth in demand over the forecast period. Subsequently, the demand for infection-free and healthy livestock used primarily for consumption is increasing. However, the prevalence of various microbial infections is high in both humans and animals. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, zoonotic diseases are common in the U.S. and worldwide and over 6 out of every 10 known infectious diseases in humans are spread from animals. Hence, antibiotics are an important medication for livestock that aide in providing healthy food products for consumption in humans. This factor is driving the growth of the segment in the forecast period.
The major factors responsible for the growth of this segment include the efficiency of tylosin in various diseases or conditions, such as chronic respiratory disease (CRD) associated with Mycoplasma Gallisepticum and Mycolplasma synoviae and other infections.
According to National Center for Biotechnology Information (NCBI), 2015, around 80% of antibiotics sold in the U.S. are for livestock and almost 70% of these are medically important. Moreover, according to NCBI, the antimicrobial consumption in livestock is expected to increase by 67% by 2030, and nearly double. These factors are expected to boost the global Tylosin market growth over the forecast period.
Moreover, antibiotics such as tylosin are used in various animal species for prevention of mycoplasmosis. For instance, animals such as chickens, turkeys, pigs, and calves require oral Tylosin to be administered in required dosage to prevent mycoplasmosis and to grow healthy livestock. Furthermore, livestock is a major source of income in several of the emerging economies such as Brazil, which is major factor expected to contribute in growth of the market in the region over the forecast period.
North America region is dominating the global tylosin market accounted for the largest market share in 2019, owing to a wide range of definitive measures adopted by government animal welfare organizations that are consistently working for overall improvement in animal health.
Apart from the high prevalence of GI disorders, the changing lifestyle, unhealthy eating habits, and high disposable income are contributing to the high growth rates. On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period. Furthermore, technological advancements, rising incidence of zoonotic diseases, and increasing number of pet owners are expected to boost the market in this country. Collaborative efforts undertaken by major companies to enhance their R&D capabilities and ensure high quality standards are also anticipated to impel demand across this region. Also, the steady importance given to agricultural contribution to these countries makes the owner more responsible for better care of farm animals. The healthcare expenditure compared to other countries, also fuels the market growth in North America. Thus, it should hold a major share of the market, over the forecast period.
The tylosin market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, Elanco Animal Health, Apeloa Kangyu and Top Pharm Chemical Group among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the tylosin market globally.
Overview: Elanco Animal Health Incorporated operates as an animal health care company. The Company develops, manufactures, and markets products for companion and food animals. Elanco Animal Health serves clients worldwide. Elanco Animal Health is located in BASINGSTOKE, United Kingdom and is part of the Pharmaceutical Manufacturing Industry. Elanco Animal Health has 49 employees at this location and generates $8.66 million in sales (USD).
Product Portfolio: The Company's portfolio comprised of Farm Animal Products & Services, Pet Animal Products & Services, and Care4Pigs.
The global tylosin market report would provide an access to an approx. 60 market data table, 52 figures and 250 pages.
LIST NOT EXHAUSTIVE